🇺🇸 FDA
Pipeline program

HYDROXYCHLOROQUINE, METHOTREXATE, Remsima 120 mg solution for injection in pre-filled pen, METHOTREXATE, IBUPROFEN, Placebo (To evaluate the efficacy and safety of CT-P13, and mainatain blindness during the study, Placebo will be administered.), PARACETAMOL, FOLIC ACID, HYDROCORTISONE

CT-P13 3.11

Phase 3 small_molecule active

Quick answer

HYDROXYCHLOROQUINE, METHOTREXATE, Remsima 120 mg solution for injection in pre-filled pen, METHOTREXATE, IBUPROFEN, Placebo (To evaluate the efficacy and safety of CT-P13, and mainatain blindness during the study, Placebo will be administered.), PARACETAMOL, FOLIC ACID, HYDROCORTISONE for Rheumatoid arthritis is a Phase 3 program (small_molecule) at Celltrion Healthcare Hungary Kft. with 1 ClinicalTrials.gov record(s).

Program details

Company
Celltrion Healthcare Hungary Kft.
Indication
Rheumatoid arthritis
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials